- Home
- LILAK vs ATAI Comparison
LILAK vs ATAI Comparison
Compare LILAK & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LILAK | ATAI |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | Bermuda | Netherlands |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LILAK | ATAI |
|---|---|---|
| Price | $8.52 | $4.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.85 | ★ $14.00 |
| AVG Volume (30 Days) | 673.0K | ★ 3.6M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $3,018,000.00 |
| Revenue This Year | $1.62 | $943.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 811.78 |
| 52 Week Low | $4.23 | $1.15 |
| 52 Week High | $9.13 | $6.75 |
Technical Indicators
Market Signals| Indicator | LILAK | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.66 | 44.63 |
| Support Level | $8.35 | $4.25 |
| Resistance Level | $8.81 | $4.63 |
| Average True Range (ATR) | 0.27 | 0.22 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 21.79 | 52.91 |
Price Performance
Historical ComparisonAbout LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.